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Background: The measurement properties of instruments used to assess functional capacity, physical activity and
muscle strength in participants with non-small cell lung cancer (NSCLC) have not been systematically reviewed.
Method: Objectives: To identify outcome measures used to assess these outcomes in participants with NSCLC; and
to evaluate, synthesise and compare the measurement properties of the outcome measures identified. Data
Sources: A systematic review of articles using electronic databases MEDLINE (1950–2012), CINAHL (1982–2012),
EMBASE (1980–2012), Cochrane Library (2012), Expanded Academic ASAP (1994–2012), Health Collection Informit
(1995–2012) and PEDRO (1999–2012). Additional studies were identified by searching personal files and cross
referencing. Eligibility Criteria for Study Selection: Search one: studies which assessed functional capacity, physical
activity or muscle strength in participants with NSCLC using non-laboratory objective tests were included. Search
two: studies which evaluated a measurement property (inter- or intra-rater reliability; measurement error; criterion or
construct validity; or responsiveness) in NSCLC for one of the outcome measures identified in search one. Studies
published in English from 1980 were eligible. Data Extraction and Methodological Quality Assessment: data
collection form was developed and data extracted. Methodological quality of studies was assessed by two
independent reviewers using the 4-point COSMIN checklist.
Results: Thirteen outcome measures were identified. Thirty-one studies evaluating measurement properties of the
outcome measures in participants with NSCLC were included. Functional capacity was assessed using the six- and
twelve-minute walk tests; incremental- and endurance-shuttle walk tests; and the stair-climbing test. Criterion
validity for three of these measures was established in NSCLC but not the reliability or responsiveness. Physical
activity was measured using accelerometers and pedometers. Only the construct validity for accelerometers and
pedometers was reported. Muscle strength was measured using hand-held dynamometry, hand-grip dynamometry,
manual muscle test, one-repetition maximum and the chair-stand test, however only two studies reported reliability
and measurement error and one study reported construct validity.
Conclusion: Currently there is a gap in the literature regarding the measurement properties of commonly used
outcome measures in NSCLC participants, particularly reliability, measurement error and responsiveness. Further
research needs to be conducted to determine the most suitable outcome measures for use in trials involving
NSCLC participants.
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Non-small cell lung cancer (NSCLC) is associated with
significant disease burden, impaired physical status and
diminished physical activity [1,2]. Due to the disease and
treatment (surgery, chemotherapy and or radiotherapy)
adverse physiological and psychological effects are prevalent
in NSCLC, particularly exercise intolerance, weakness and
impaired gas exchange and commonly a cycle of functional
decline ensues [1]. Increasingly exercise interventions
targeted at preventing the functional decline associated
with NSCLC or improving the physical status prior to or
after cancer treatment are the focus of research trials [3].
Three commonly used endpoints are functional capacity
“the maximal capacity of an individual to perform aerobic
work or maximal oxygen consumption” [4]; physical
activity “any bodily movement produced by skeletal
muscles that results in energy expenditure” [5]; and
muscle strength “the maximum voluntary force or
torque brought to bear on the environment under a
given set of test conditions” [6]. The gold standard instru-
ments (outcome measures) to assess these outcomes are
laboratory based, which are not always feasible for use in
research or clinical practice [7]. Therefore, a wide variety
of instruments have been used to assess changes in these
outcomes in the NSCLC literature.
When selecting the most appropriate outcome measure
the clinician or researcher should consider the measure-
ment properties established for their population of interest.
Reliability determines the ability of an instrument to obtain
data which are accurate, consistent and have small
measurement errors when the instrument is repeated
longitudinally (intra-rater reliability) or by multiple
examiners (inter-rater reliability) [8,9]. Validity deter-
mines the ability of an instrument to measure what it
is intended to measure, that is, how well the data relate
to data obtained from the gold standard instrument
(criterion-concurrent validity); how well data predict
an outcome (criterion-predictive validity); or how well
an instrument obtains data, as hypothesised, when
compared to an instrument measuring a similar con-
struct (construct validity) [8,9]. Responsiveness deter-
mines the ability of an instrument to detect meaningful
change over time [9].Whilst a test may have excellent
reliability, validity and responsiveness in one clinical
population, these findings cannot always be extrapolated
to other populations [9].
This review is designed to capture outcome measures
applicable for use in the clinical setting by health
professionals or researchers. The COnsensus-based
Standards for the selection of health status Measurement
INstruments (COSMIN) guidelines and the Preferred
Reporting Items for Systematic Reviews and Meta-analyses
(PRISMA) guidelines have been followed to report this
review [8,10,11].Objectives
1. To identify non-laboratory outcome measures which
have been used to assess functional capacity, physical
activity or muscle strength in participants with NSCLC;
2. To evaluate, synthesise and compare the measurement
properties established in participants with NSCLC for
each of the outcome measures identified.
Method
Protocol
No protocol had been previously published for this review.
The search for this systematic review was conducted in
two parts. Search 1 identified studies which used an out-
come measure to assess functional capacity, physical activity
or muscle strength in participants with NSCLC. This initial
search allowed a list of outcome measures to be generated.
Search 2 identified studies which examined the measure-
ment properties of the outcome measures identified in
Search 1, specifically in participants with NSCLC.
Search 1: outcome measures
Eligibility criteria
Studies This review considered any type of quantitative
study design as defined by the National Health and Medical
Research Council Classification [12]. Full manuscripts
published in English in a peer reviewed journal from
1980 onwards were eligible.
Participants Participants of any age, diagnosed with
NSCLC, at any stage of the disease were considered.
NSCLC was defined as: carcinoma of the lung including
adenocarcinoma, squamous cell carcinoma and large cell
carcinoma [13]. At least five participants with NSCLC were
required for the study to be included. Studies which in-
cluded mixed cancer cohorts were also eligible providing at
least five participants were diagnosed with NSCLC. The au-
thors were contacted for studies which did not specify the
type of lung cancer to confirm the number of participants
with NSCLC. Studies without original participant data
(such as reviews, narratives or editorials) were excluded.
Outcomes Outcomes of interest were objective tests
which, based on face validity, aimed to measure functional
capacity, physical activity or muscle strength in the clinical
setting. Outcome measures conducted in a laboratory were
excluded. Patient-reported outcome measures, such as
questionnaires, were excluded.
Information sources, search and study selection
Prior to conducting this review the Cochrane Library
(including the Cochrane Database of Systematic Reviews
and Database of Abstract of Review of Effectiveness
DARE), Physiotherapy Evidence Database (PEDro), the
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properties [14] and the International Prospective Register
of Systematic Reviews (PROSPERO) [15] were searched to
ensure no similar reviews had been published. Seven
electronic databases were searched by one reviewer
(CG) using a systematic, comprehensive and reprodu-
cible search strategy to identify all published studies
(Additional file 1). Databases were accessed via The
University of Melbourne and Austin Health, Australia,
with the last search run on 4-October-2012.
Search terms used were: lung cancer, NSCLC, fitness,
exercise, exercise capacity, functional capacity, function,
acceleromet*, physical activity monitor*, global positioning
system, strength, walk*, ambulat*, pedometer*, gait, out-
come, assessment, test*, functional assessment, outcome as-
sessment, exercise test, treatment outcome, data collection.
A standardised eligibility assessment was performed by two
independent reviewers (CG, SP) (Additional file 1). All
studies identified by the search strategy were assessed based
on title/abstract for eligibility. If there was insufficient infor-
mation to include/exclude a study, full-text was retrieved.
Consensus was required by both reviewers. Full-text of all
relevant studies was obtained and read to ensure the
inclusion criteria were met. Disagreements were settled by
a third independent reviewer (LD). If there was insufficient
information to include/exclude an article, the authors were
contacted where possible. At each assessment stage
agreement between reviewers was estimated with per-
centage agreement and the Kappa statistic using SPSS
for Windows statistical software package (IBMW SPSSW
Statistics Version20.0.0) [16]. All references were stored
in Endnote software 2010 versionX4.Data collection process
A data collection form was specifically developed and used
to extract data from studies by one reviewer (CG) and a sec-
ond reviewer cross-checked extracted data (SP). To avoid
double counting data, multiple reports on the same patient
group were identified by juxtaposing study details. Collected
data were stored in Microsoft(R) Office Excel(R)2007.Search 2: measurement properties
Eligibility criteria
Studies Studies which aimed to develop an outcome
measure or evaluate the measurement properties of an
outcome measure identified in Search 1 were eligible.
Only studies published in a peer reviewed journal were
included. Conference abstracts or studies not published
in a peer reviewed journal were excluded due to the
inability to effectively evaluate risk of bias of the individual
study. Only studies published from 1 January 1980 that
were available in English were eligible.Participants Participants of any age, diagnosed with
NSCLC, at any stage of the disease were considered.
NSCLC was defined as: carcinoma of the lung including
adenocarcinoma, squamous cell carcinoma and large cell
carcinoma [13]. At least five participants with NSCLC
were required for the study to be included. Studies
which included mixed cancer cohorts were also eligible
providing at least five participants were diagnosed with
NSCLC. The authors were contacted for studies which
did not specify the type of lung cancer to confirm the
number of participants with NSCLC. Studies without
original participant data (such as reviews, narratives or
editorials) were excluded.
Outcomes Outcomes of interest were the measurement
properties: reliability (inter- or intra-rater), measurement
error, criterion validity (concurrent or predictive), construct
validity (hypothesis testing) and responsiveness of outcome
measures identified in Search 1 [8]. Studies validating an
alternative test against an outcome measure of interest
(which provide indirect evidence for validity) and longitu-
dinal studies (which provide indirect evidence for respon-
siveness) were excluded because such studies have not
specifically formulated or tested hypotheses about the
measurement properties [8]. Studies evaluating a battery
measure including a relevant sub-component were also
excluded as they are designed to be used in their entirety.
Information sources, search and data extraction
Four electronic databases were searched by one reviewer
(CG) using a systematic, comprehensive and reproducible
search strategy (Figure 1). The last search was run on 4-
October-2012. A previously published search filter was used
(sensitivity 97.4%; precision 4.4%) (Additional file 2) [17].
No publication date or language restrictions were imposed
on the search. The study selection and data collection
processes followed were the same as described for
Search 1. Data items extracted were adapted from the
COSMIN generalizability checklist [10].
Risk of bias of studies
Two independent reviewers (CG, CO) evaluated risk of
bias using the 4-point COSMIN checklist [18]. This
checklist was originally developed to assess the meth-
odological quality of patient-reported outcome measures
however it has also been suggested for use to assess the
quality of non-patient reported outcome measures [10].
Four items from the checklist (internal consistency, struc-
tural validity, cross-cultural validity and content validity)
are only applicable to questionnaires and were therefore
not assessed [19]. Questions for remaining items (reliability,
measurement error, hypothesis testing, criterion validity
and responsiveness) were scored on a 4-point scale. The
overall score for each item was obtained by using the lowest
Records (title / abstract) assessed for eligibility by two independent reviewers (CG, SP)
CR n = 3 CR n = 10CR n = 12 CR n = 5CR n = 15 
Records identified through database searching: 
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Figure 1 Flow diagram of measurement properties study selection process – Search 2. Abbreviations: 1RM, one repetition maximum;
6MWT, six-minute walk test; 12MWT, twelve-minute walk test; Acc, accelerometer; CINAHL, Cumulative Index to Nursing and Allied Health
Literature; CR, cross referencing; CST, chair-stand test; ESWT, endurance-shuttle walk test; EMBASE, the Excerpta Medica Database; excl, excluded;
HHD, hand-held dynamometry; HGD, hand-grip dynamometry; ISWT, incremental-shuttle walk test; MMT, manual muscle test; n, number; NSCLC,
non-small cell lung cancer; OM, outcome measure; Pedom, pedometer; S1, search from part one; SCT, stair-climb test.
Granger et al. BMC Cancer 2013, 13:135 Page 4 of 19
http://www.biomedcentral.com/1471-2407/13/135score (excellent, good, fair or poor) recorded for any ques-
tion within the item, as recommended by the COSMIN
scoring system [18]. Reviewer agreement was estimated
with percentage agreement and the Kappa statistic [16].
Results
Search 1: outcome measures
The search of seven electronic databases and cross
referencing identified 6,398 studies. Assessment of
title/abstract and full text results in 88 articles using 13
different outcome measures being included (Figure 1;
Additional file 1). A list of outcome measures was
generated (Table 1). Almost perfect agreement between
reviewers of potentially relevant titles/abstracts (CG, SP)(97.0%, Kappa=0.93) and full-text articles (CG, SP) (94.5%,
Kappa=0.82) was obtained [16]. The third reviewer (LD)
was consulted twice. Twenty-two authors were contacted
to clarify the cancer type, 13 responded. In ten cases the
lung cancer type could not be confirmed and these studies
were excluded.
Search 2: measurement properties
Study selection
The search identified 375 studies of which 34 articles
(31 studies) were included (Figure 1). Almost perfect
agreement was obtained between reviewers (CG, SP) for
titles/abstracts (96%, Kappa=0.92) and substantial agree-
ment was obtained for full-text articles (90%, Kappa=0.78)
Table 1 Synthesis of evidence regarding measurement properties: comparison of outcome measures




Criterion predictive validity Construct validity
(hypothesis testing)
Functional capacity
6-minute walk test x x 8 studies [22-27,39-41], predicts:
survival, post-op outcomes
(complications, LOS, 6MWT,
HRQoL) and development of RP
1 study [26,27], strongly
correlated with RFT
12-minute walk test x x x x
Incremental-shuttle walk test x 1 study [30], strongly
correlated with CPET
2 studies [30,64], predicts:
survival and post-op outcomes
3 studies [30,44,64], moderately
correlated with muscle strength;
little, moderate and strong
correlation with RFT; little
correlation with mastery
questionnaire
Endurance-shuttle walk test x x x x






2 studies [20,31], strong
correlation between VO2peak
and altitude reached; direct
association between pre and
post-op SCT results
Physical activity
Accelerometer x x x 3 studies [46-51], strongly
correlated with estimated EE
and sleep; moderately correlated
with depression, HRQoL and PS
Pedometer x x x 1 study [53], moderately
correlated with CPET
Muscle strength
Hand-held dynamometry x x x x
Hand-held dynamometry
with pulley force sensor




Hand-grip dynamometry 1 study [28], moderate
intra-rater reliability
x x x
Manual-muscle test x x x x
One-repetition maximum x x x x
Chair-stand test x x x 1 study [53], moderately
correlated with PS and fatigue
Abbreviations: 6MWT, six-minute walk test; CPET, cardio-pulmonary exercise testing; EE, energy expenditure; HRQoL, health related quality of life; ICC, intraclass
correlation coefficient; LOS, length of hospital stay; post-op, post-operative; pre-op, pre-operative; PS, Performance Status; RFT, respiratory function tests; RP,
radiation pneumonitis; SCT, stair-climb test; SEM, standard error of measurement; VO2peak, peak oxygen consumption.
x = not assessed.
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type, nine responded. In seven cases the lung cancer type
could not be confirmed and these studies were excluded.
Study characteristics
Table 2 summarises the 31 prospective observational
studies. The majority of studies included only partici-
pants with NSCLC (n=18, 58%). Studies had a mean
(standard deviation [SD]) sample size of 130 (146) partici-
pants (range 12–640). Outcome measures were longitudin-
ally repeated in 25% of studies: before and after surgery
(n=5, 16%) [20-24], chemotherapy (n=1, 3%) [25] and
radiotherapy (n=2, 6%) [26-28] (Table 3).Outcome measures
Measurement properties evaluated were: intra-rater
reliability (studies n=1); inter-rater reliability (n=1);
measurement error (n=1); criterion-concurrent validity
(n=2); criterion-predictive validity (n=20); construct validity
(hypothesis testing) (n=11) and responsiveness (n=0)
(Table 1; Table 4; Additional file 3).
Risk of bias of studies
Risk of bias was assessed by independent reviews (CG, CO)
achieving a percentage agreement of 87%, Kappa=0.80 [16].
Consensus was achieved on 100% of occasions that re-
viewers disagreed. Overall studies evaluating validity scored
Table 2 Study characteristics – part 2




OM Setting (n)% / method
of pt selection
Cancer type (n)% Cancer stage (n)% Cancer treatment at
baseline time-point (n)%
Functional capacity
Jones 2012 USA [40] 118 71/47 61 ± 10 6MWT Health system /
consecutive
NSCLC IIIB, IV, recurrent IV Chemo (70) 59%; RT (10) 8%;
post-op (27) 23%; post-chemo
(55) 47%; post-RT (54) 46%
Pancieri 2010 Brazil [22] 40 22/18 48 ± 16 6MWT;
SCT
Hospital / consecutive NSCLC (33) 82.5%; other LC
(2) 5%; benign (5) 12.5%
NR Pre-op LR
Kasymjanova 2009 Canada [25] 64 29/35 62.0 ± 10.8 6MWT Outpt clinic / consecutive NSCLC III (8) 12%; IV (56) 87% Pre-chemo
Mao 2007* Miller 2005 USA [26,27] 53 28/25 64 (range 45–81) 6MWT Hospital/ sample part of
larger prospective trial
NSCLC (39) 74%; SCLC (12) 23%;
meso (1) 2%; lung met (1) 2%
NSCLC only: I – II (4)
8%; III-IV (41) 77%;
recurrent (8) 15%
Pre- RT (17) 32%; pre-chemo-RT
(36) 68%; prior chemo (33) 62%;
Saad 2007 Brazil [24] 36 20/16 Median 55.5 ± 13.4 6MWT Hospital / consecutive NSCLC (26) 72%; lung met (8)
22%; sarcoma (2) 6%
NR Pre-op LR
Parsons 2003 Canada [39] 70 40/30 65 (range 29–83) 6MWT
SCT
Hospital / convenience NSCLC (55) 79%; pulmonary
met (11) 16%; meso (2) 3%;
benign (2) 3%
NR Pre-op LR
Pierce 1994 Australia [23] 54 54/0 67 ± 7 6MWT Hospital / consecutive LC (including NSCLC) NR Pre-op LR
Holden 1992 USA [41] 16 13/3 68 ± 9.3 6MWT;
SCT
Hospital NSCLC (15) 94%; SCLC (1) 6% I (10) 62%; II (3) 19%; III
(2) 12%; IV (1) 6%
Pre-op LR
England 2012 UK [44] 41 21/20 64 ± 8 ISWT Outpt clinic NSCLC (26) 63%; meso (11)
27%; SCLC (4) 10%
Local (21) 51%;
advanced (20); 49%
Post pall-chemo (26) 63%; post
pall-RT (10) 24%; post-RT (1) 2%
Win 2006 UK [30] 125 81/44 68.8 ± 7.7 ISWT Consecutive NSCLC NR Pre-op LR
Win 2004 UK [64] 111 71/40 69 (range 42–85) ISWT Outpt clinic NSCLC (107) 96%; miscellaneous
(4) 4%
I-IIIA Pre-op LR
Brunelli 2012 Italy [43] 282 218/64 68.0 ± 9.8 SCT Tertiary referral centre /
consecutive
NSCLC I (118) 42%; other
(164) 58%
Pre-op LR
Brunelli 2010 Italy [31] 109 83/26 66.6 ± 11.1 SCT Tertiary referral centre /
consecutive
NSCLC NR Pre-op LR
Brunelli 2008a Italy [34] 536 426/110 67 ± 9 SCT Tertiary referral centre /
consecutive
NSCLC I (206) 38% ; > I
(330) 62%
Pre-op LR (536) 100%; chemo
(56) 10%
Brunelli 2008b Italy [33] 640 NR 66.7 ± 9.3 SCT Tertiary referral centre /
consecutive
NSCLC NR Pre-op LR (640) 100%;
neoadjuvant chemo (100) 16%
Koegelenberg 2008 South
Africa [29]
44 31/13 47.6 ± 12.5 SCT Tertiary referral centre /
consecutive
NSCLC (13) 29%; benign (31) 70% NR Pre-op LR
Nikolic 2008 Croatia [36] 101 82/19 61.1 ± 8.4 SCT Hospital / consecutive NSCLC NR Pre-op LR
Brunelli 2007 Italy [20] 200 NR 66.8 ± 9.1 SCT Tertiary referral centre /
consecutive
NSCLC NR Pre-op LR (200) 100%;
neoadjuvant chemo (19) 9.5%
Toker 2007 Turkey [37] 150 127/23 59.3 ± 10.3 (gp 1)
60.7 ± 10.9 (gp 2)
SCT University hospital /
consecutive


















Table 2 Study characteristics – part 2 (Continued)
Brunelli 2005 Italy [42] 391 309/82 69.1 ± 8.3 (gp 1)
67.0 ± 9.0 (gp 2)
SCT Tertiary referral centre /
consecutive
NSCLC NR Pre-op LR
Brunelli 2004 Italy [35] 109 NR 75.2 ± 3.0 SCT Tertiary referral centre /
consecutive
NSCLC I (23) 21% ; > I (86) 79% Pre-op lobectomy
Brunelli 2003 Italy [21] 227 NR 66.4 ± 9.1 (gp 1)
66.8 ± 8.1 (gp 2)
SCT Tertiary referral centre /
consecutive
NSCLC NR Pre-op LR
Brunelli 2002 Italy [32] 160 128/32 66.2 ± 9.6 SCT Tertiary referral centre /
consecutive
NSCLC NR Pre-op LR
Pate 1996 USA [38] 12 10/2 63.6 ± 4.9 SCT Three university
hospitals / consecutive




Maddocks 2012 UK [47] 84 54/30 66 ± 9 Acc Outpt clinic NSCLC (71) 84%; SCLC (8) 9%;
meso (5) 6%
IIIB (43) 51%; IV (41) 49% Palliative Rx
Grutsch 2011a, 2011b;
Du-Quiton 2010 USA [48-50]
84 65/19 62 (range 40–94) Acc Hospital inpt (42) 50%;
home (42) 50%
NSCLC II (1) 1%; III (18) 21%;
IV (65) 77%
Pre-chemo (84) 100%; prior Rx
(31) 37%
Maddocks 2010 UK [46] 60 40/20 68 ± 9 Acc Outpt clinic NSCLC (53) 88%: meso (5)




Novoa 2011 Spain [51] 38 30/8 62.8 ± 10.1 Pedom Output clinic /
consecutive
NSCLC NR Pre-op LR
Muscle strength
Trutschnigg 2008 Canada [28] 74 48/26 61.5 ± 13.1 HGD Hospital and laboratory NSCLC; GI Advanced NR
Brown 2005 UK [53] 53 30/23 Median 64
(range 43–81)
HGD CST Palliative care centre x 2
and hospital
Gp1: healthy controls (15) 100%
Gp2: cancer: NSCLC (29) 76%; SCLC
(6) 16%; no histology LC (3) 8%
Locally advanced (20)
53%; IV (18) 47%
NR




NSCLC (7) 17.5%; other LC (3) 7.5%;
haem (20) 50%; sarcoma (5) 12.5%;
seminoma (3) 7.5%; other (2) 5%
I-IV Chemo
Abbreviations: 6MWT, six-minute walk test; Acc, accelerometer; ca, cancer; chemo, chemotherapy; CST, chair-stand test; F, female; gp, group; gyn, gynaecological; haem, haematological; GI, gastro-intestinal; HHD, hand-
held dynamometry; HGD, hand-grip dynamometry; HT, hormone therapy; ISWT, incremental shuttle walk test; inpt, inpatient; LC, lung cancer; LR, lung resection; M, male; meso, mesothelioma; met, metastasis; n, number
of participants; NR, not reported; NSCLC, non-small cell lung cancer; OM, outcome measure; outpt; outpatient; pall, palliative; pedom, pedometer; PFS, pulley-force sensor; post-op, post-operative; pre-op, pre-operative;
pt, participant; RT, radiotherapy; Rx, treatment; stair, stair-climbing test; SCLC, small cell lung cancer; SCT, stair-climb test; SD, standard deviation; wks, weeks; yr, year published; yrs, years.






















Encouragement standardised Number of repeat
Ax in testing session
Jones 2012 [40] Yes [50] NR NR
Pancieri 2010 [22] No ‘encouraged walking’ NR
Kasymjanova
2009 [25]




Yes [20] NR NR
Saad 2007 [24] Yes [50] NR NR
Parsons 2003 [39] Yes [34,68-72] Yes 1 x practice, 1 x actual
Pierce 1994 [23] Yes [73] NR 3 (best value used)
Holden 1992 [41] No NR 2 (15-30 min interval)
ISWT OM procedure
referenced
Encouragement standardised No of repeat Ax in
testing session
Additional description
England 2012 [44] Yes [59] NR 1 x practice,
1 x actual
Participants wore COSMED K4 b2
system (COSMED, Italy) to measure
HR, VE and VO2 throughout test
Win 2006; 2004
[30,64]
Yes [59] NR 1 HR and SpO2 monitored and recorded
at 30 second intervals throughout test
SCT Equipment Monitoring
during test
Intensity Outcome Number of repeat















Pace of pt choice, asked to
climb max no steps and stop
for exhaustion, limiting SOB,
leg fatigue or chest pain




SpO2 < 90% or
fall >4%)
1 Physician Calculations from test:
• Work = (step height in meters x
steps per min x body weight in
kg x 0.1635)[74]
• VO2max (ml/min) = 5.8 x weight
in kg + 151 + 10.1 x work) [74]
• VO2max corrected for body surface
area (ml/min2) = VO2max / max HR
Pancieri 2010 [22] 6 flights x 12 steps
(16.9 cm height),
30° incline
HR, SpO2 Climb all steps in the shortest
possible time with verbal
encouragement between flights.
Testing stopped for fatigue,




















Table 3 Description of outcome measures used (Continued)
Koegelenberg
2008 [29]
12 flights x 10 steps
(3.48 m b/t floors)
HR, SpO2 Pt asked to climb ‘as fast and as
high’ as they possibly could to a
max elevation of 20 m
Altitude, time taken,
speed of ascent
NR NR Stair climb considered completed
if pt rested or more than 3 seconds
or reached 20 m height Allowed to
use rail only for balance





Pace of pt choice, asked to climb
max no steps and stop for
exhaustion, limiting SOB, leg
fatigue or chest pain
No steps, time
taken
1 Physician Pt instructed not to use hand-rail
Toker 2007 [37] 20 steps per flight
(15 cm height)








Pate 1996 [38] 21 steps per flight
(17.5 cm height)
HR, SpO2 Moderate pace of pts choice,
encouraged to exercise to a
symptom-limited max and
complete the flight of stairs they




1 NR Test considered completed as soon
as patient stopped for any reason
Pt instructed not to use hand-rail
Holden 1992 [41] 11 steps per flight
(0.17 m height)
SpO2 Own pace Altitude, time taken 1 Therapist Calculations from test:
• Work = step height x steps per
min x weight in kg x 0.1635
• VO2 ml/min = 5.8 x weight in
kg + 151 + (10.1 x work)










Mean daily step count, number
of sit-to-stand transitions, time in
hrs spent sitting/lying, upright
standing and upright stepping
7 days (6 full
days of data)
Mid-third of anterior












Mean duration daytime activity
(no of vertical/horizontal
accelerations per min)
3-7 days Non-dominant wrist
Novoa 2011 [51] OMROM Walking
Style ProW pedometer
Home environment Mean daily no total and aerobic
steps; mean daily distance
walked (km); mean daily time
















optimal duration of monitoring
7 days (6 full
days of data)
Mid-third of anterior


















Table 3 Description of outcome measures used (Continued)








Home environment Mean daily step count, number
of sit-to-stand transitions, time
in hrs spent sitting/lying, upright
standing and upright stepping
7 days (6 full
days of data)
Mid-third of anterior











Mean duration daytime activity
(no of vertical/horizontal
accelerations per min)
3-7 days Non-dominant wrist
Novoa 2011 [51] OMROM Walking Style
ProW pedometer
Home environment Mean daily no total and aerobic
steps; mean daily distance
walked (km); mean daily time
















optimal duration of monitoring
7 days (6 full
days of data)
Mid-third of anterior
thigh of dominant leg
Muscle strength Equipment Muscle group
movement
Participant position No of assessors Number of repeat








position 3 on handle
Grip Sitting, feet on ground shoulder
width apart, Elb 90 ° F, wrist 0°,
arm on arm rest [75]
NR 1-2 x practice
2 x 3reps actual
(mean value used)
NR Dominant hand Patient instructed
when to start and stop contraction
with a 3 second contraction time
No encouragement
Brown 2005 [53] Square design chair
with firm seat 43 cm
height and arm rests
Sit to stand Seated NR NR NR Pt asked to rise from seated position
to fully upright position as fast as
they could, if possible without
using arm rests
Knols 2002 [52] Mecmesin FB50K
pull-gauge HHD,
Mecmesin, England
Elb E, Knee E 1. Supine, Elb 90 °F, upper edge
pull- attachment perpendicular
to ulnar side of forearm distal to
caput ulnae, non-elastic belt
over ASIS stabilised pt on table
2 (random order)
30 min interval
6 x practice 3 x actual
(60 second interval)
Physiotherapist Dominant UL and LL Ax – identified
by asking participant to throw a ball
and kick a ball (preferred stance leg
chosen) Figures also provided for
both testing positions ‘Make’ test
used Pt asked to increase force
over 2 seconds and maintain for
another 5 seconds
2. sitting edge of table upright no
back support, knee 90 °F, stabilise
trunk by grasping table, lower
edge pull-attachment
perpendicular to ant surface tibia,
distal to end med mall
Abbreviations: 1RM, one repetition maximum; 6MWT, six-minute walk test; ant, anterior; ASIS, spinae iliacae ant superiorum; ATS, American Thoracic Society; Ax, assessment; bt, between; cm, centimeters; dyn,
dynamometer; E, extension; Elb, elbow; F, flexion; HHD, hand held dynamometer; HGD, hand grip dynamometer; HR, heart rate; hrs, hours; ISWT, incremental shuttle walk test; kg, kilograms; km, kilometers; L, left; LL,
lower limb; m, meters; mal, malleolus; max, maximum; med, medial; METh, metabolic equivalent hours; min, minutes; ml, millimetres; NA, not applicable; no, number; NR, not reported; OM, outcome measure; pt,



















Table 4 Criterion-concurrent validity, criterion-predictive validity and construct validity of outcome measures
Author, yr Type of validity
and OM
Missing values Comparator OM or predicted outcome Validation results
Functional capacity
Jones 2012 [40] Crit-pred 6MWT Nil All-cause mortality Unadjusted HR p = 0.003; Compared to 6MWT
<358.5 m adjusted HR = 0.61 (95% CI 0.34-1.07)
if 6MWT 358.5-450 m; Compared to 6MWT <385.5 m
adjusted HR = 0.48 (95% CI 0.24-0.93) if 6MWT >450 m
Pancieri 2010 [22] Crit-pred 6MWT NR Predicted post-op 6MWT = pre-op
6MWT x (FS – resected FS) ÷ FS
r = 0.40, p<0.01
Kasymjanova 2009 [25] Crit-pred 6MWT 19pts dropped out Survival Compared to 6MWT ≥ 400 m mortality HR = 0.44
(95% CI 0.23-0.83) if 6MWT <400 m, p = 0.001
Mao 2007* Miller 2005 [26,27] Crit-pred; construct 6MWT 3pts not complete Ax 1. Development of RP 1. ROC area under curve = 0.41, p = 0.4
2. FEV1 2. r = 0.53, p<0.001
3. FVC 3. r = 0.44, p = 0.001
4. DLCO 4. r = 0.48, p<0.001
Saad 2007 [24] Crit-pred 6MWT 9pts died; 30pts not
complete Ax (rural)
Predictors of improvement in
pre-op to 180 days-post-op:
1. GEE = 0.001, SE = 0.000, p = 0.003
1. SF-36 PF 2. GEE = 0.001, SE = 0.000, p = 0.000
2. SF-36 PR 3. GEE = 0.001, SE = 0.000, p = 0.031
3. SF-36 GH
Parsons 2003 [39] Crit-pred 6MWT 29pts LOS out of hospital < 30 days post-op Not significant
Pierce 1994 [23] Crit-pred 6MWT NR Post-op: 1. p<0.05
1. respiratory failure 2. p>0.05
2. surgical POC 3. p>0.05
3. respiratory POC 4. p>0.05
4. cardiac POC 5. p>0.05
5. all POC
Holden 1992 [41] Crit-pred 6MWT 3pts not complete Ax Survival > 90 days post-op 6MWT diff b/t groups with/without survival p<0.05;
6MWT > 1000feet (305 m) pre-op sensitivity 100%,
positive predictive value 85%, negative predictive
value 100% for survival
England 2012 [44] Construct ISWT Nil 1. P max monitor (insp mm strength) 1. r = 0.42, p = 0.01
2. dynamometry (peripheral mm power) 2. r = 0.39, p = 0.01
3. spirometry (% predicted FEV1) 3. r = 0.22, p = 0.17
4. spirometry (% predicted FVC) 4. r = 0.21, p = 0.2


















Table 4 Criterion-concurrent validity, criterion-predictive validity and construct validity of outcome measures (Continued)
Win 2006 [30] Crit-pred; crit-concurrent;
construct ISWT
Nil 1. CPET (VO2peak) 1. r = 0.67, p<0.001
2. CPET (VO2peak% predicted) 2. r = 0.30
3. spirometry (FEV1) 3. r = 0.5
4. 12 month survival 4. ROC area = 0.7, p = 0.003
Win 2004 [64] Crit-pred, construct ISWT 8pts 1. poor surgical outcome (post-op death,
MI, heart failure, resp failure, septicaemia,
pneumonia, cardiac arrthymia)
1. p = 0.6 between poor and sufficient outcome groups
2. FEV1 2. r = 0.46, not significant
Brunelli 2012 [43] Crit-pred SCT 14 Median survival and 5-year survival Altitude >18 m independent predictor: HR = 0.5, p = 0.003
Brunelli 2010 [31] Construct SCT Nil SCT (VO2max) Altitude: correlation coefficient = 0.7, p<0.0001
Speed of ascent: correlation coefficient = 0.47, p = 0.005
Pancieri 2010 [22] Crit-pred SCT NR Predicted post-op SCT = pre-op SCT x
(FS – resected FS) ÷ FS
r = 0.66, p<0.001
Brunelli 2008a [34] Crit-pred SCT Nil POC < 30 days post-op Pre-op altitude: coefficient = −0.05, OR = 0.95 (95% CI 0.91-0.99),
SE = 0.02, p = 0.045
O2desat >4%: coefficient = 0.56, OR = 1.8 (95% CI 1–3), SE = 0.3,
p = 0.05
Brunelli 2008b [33] Crit-pred SCT Nil 1. POC < 30 days post-op 1. altitude: coefficient = 0.34, SE = 0.2, OR = 1.4 (95% CI 1.02-1.95),
p = 0.04
2. Death < 30 days post-op 2. altitude: coefficient = 0.91, SE = 0.4, OR = 2.5 (95% CI 1.1-5.5),
p = 0.02
3. Post-op hospital costs 3. altitude: coefficient = 2160.2, SE = 573, p<0.001
Koegelenberg 2008 [29] Crit-concurrent SCT Nil CPET (VO2max) Altitude r
2 = 0.06, Speed of ascent r2 = 0.77 (lung cancer only)
Nikolic 2008 [36] Crit-pred SCT Nil POC < 30 days post-op Best independent predictor = SpO2 after 40 steps and SCT
duration for lobectomy group (60% sensitivity, 75% specificity cut
off value 1.09) positive LR = 2.4 (95% CI 1.71-3.38), negative
LR = 0.53 (95% CI 0.38-0.76)
Brunelli 2007 [20] Constuct SCT 53pts at 3 months Post-op SCT (VO2peak) Pre-op SCT VO2peak directly associated with post-op SCT:
regression analysis lobectomy F = 3.58, p<0.01; pneumonectomy
F = 3.53, p<0.01
Toker 2007 [37] Crit-pred SCT Nil POC (cardiac or pulmonary) SpO2 pre-SCT: OR = 0.74 (95% CI 0.58-1.00), p = 0.001
Change SpO2 pre to post-SCT: OR = 1.59 (95% CI 1.21-2.10), p = 0.018
Brunelli 2005 [42] Crit-pred SCT 13pts 1. POC < 30 days post-op Inability to perform pre-op SCT:
1. p = 0.7
2. Death < 30 days post-op 2. OR = 0.20 (95% CI 0.06-0.62), p = 0.005



















Table 4 Criterion-concurrent validity, criterion-predictive validity and construct validity of outcome measures (Continued)
Brunelli 2003 [21] Crit-pred SCT Nil O2 desat during post-op SCT O2 desat during pre-op SCT independent variable: regression
coefficient = 0.22, p = 0.0004
Parsons 2003 [39] Crit-pred SCT 29pts LOS out of hospital < 30 days post-op 1. longer LOS correlated with speed of ascent r = 0.34, p≤0.02
2. workload achieved predicted LOS out of hospital r2 = 0.130
Brunelli 2002 [32] Crit-pred SCT Nil POC < 30 days post-op Altitude independent variable: p = 0.003
Pate 1996 [38] Crit-pred SCT Nil POC < 30 days post-op Significant difference in pre-op SCT between pt who did and
did not develop POC
Holden 1982 [41] Crit-pred SCT 3pts Survival > 90 days post-op SCT diff b/t groups with/without survival p<0.05
SCT > 44steps pre-op positive predictive value 91%, negative
predictive value 80% for survival
Physical activity
Maddocks 2012 [47] Construct Acc Nil ECOG PS Statistically significant difference in mean daily step count, time
spent sitting/lying, upright, standing or stepping between
PS 0, 1 and 2 p<0.05 but not mean daily sit-to-stand transitions
Grutsch 2011a, 2011b;
Du-Quiton 2010 [48-50]
Construct Acc 16pts Acc, 16pts
questionnaires
1. HADS 1. Outpt: depression and activity r = −0.41, p = 0.04
2. Ferrans and Power QLI Cancer Version III 2. Daytime activity and QLI domains of health/functioning
r = 0.51, p<0.01; social/economic r = 0.38, p = 0.048;
psychological/spiritual r = 0.45, p = 0.02; family r = 0.45,
p = 0.02; overall QLI r = 0.57, p<0.01
3. EORTC 3. Inpt: daytime activity and loss of appetite r = −0.41, p = 0.005
4. PSQI 4. Outpt: lower sleep medication use and activity r = −0.58, p<0.01
Novoa 2011 [51] Construct Pedom 13 pts – unable to
perform exercise test
CPET (VO2max) Mean daily total steps r = 0.4
Mean daily aerobic steps r = 0.16
Mean daily time of aerobic capacity r = 0.11
Mean daily distance walked r = 0.44
Maddocks 2010 [46] Construct Acc 2 pts withdrawn Estimated EE (stepping and non-stepping)
measured from acc
Non-stepping EE and daily step count r = −0.91, p<0.01
Muscle strength
Brown 2005 [53] Construct CST Nil 1. KPS 1. r2 = 0.565, p < 0.001 (ca group)
2. FACIT-fatigue 2. with incr fatigue, lower CST p<0.01 (ca group)
Abbreviations: 6MWT, six minute walk test; 95% CI, 95% confidence intervals; acc, accelerometery; Ax, assessment; b/t, between; ca, cancer; CPET, cardio-pulmonary exercise testing; CRDQ, Chronic Respiratory Disease
Questionnaire; crit, criterion; CST, chair-stand test; desat, desaturation; diff, difference; DLCO, diffused capacity for carbon monoxide; ECOG, Eastern Cooperative Oncology Group; EE, energy expenditure; EORTC,
European Organisation for Research and Treatment of Cancer quality of life questionnaire; FACIT-fatigue, Functional Assessment of Chronic Illness Therapy- Fatigue scale; FEV1, force expired volume in one second; FS,
lung functioning segments; FVC, forced vital capacity; GEE, generalized estimation equations; HADS, Hospital Anxiety and Depression Scale; HR, hazard ratio; insp, inspiratory; inpt, inpatient; ISWT, incremental-shuttle
walk test; KPS, Karnofsky performance status; LOS, length of stay; LR, likelihood ratio; m, meters; max, maximum; MI, myocardial infarction; mm, muscle; NR, not reported; OM, outcome measure; OR, odds ratio; outpt,
outpatient; P, pressure; pedom, pedometer; POC, post-operative complication; post-op, post-operative; pre-op, pre-operative; pred, predictive; PS, performance status; pt, participant; PSQI, Pittsburgh Sleep Quality Index;
QLI, Quality of Life Index; r, correlation coefficient; ROC, received operating characteristic curve; SCT, stair-climb test; SE, standard error; SF-36, Short Form 36 physical functioning/physical role/general health domain;
resp, respiratory; RP, radiation pneumonitis; Rx, treatment; SpO2, oxygen saturation; VO2max, maximum oxygen consumption; VO2peak, peak oxygen consumption; yr, year published.
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http://www.biomedcentral.com/1471-2407/13/135‘excellent’ or ‘good’ on 12/29 occasions. No studies evaluat-
ing reliability scored ‘excellent’ or ‘good’ (Table 5). The
worst performing area for validity studies was design re-
quirements (lack of a priori hypotheses formed) and for reli-
ability studies was design requirements (small sample size).
Study results
Study results are summarised in Table 1 and the sections
below. The stair-climbing test, six-minute walking testTable 5 Methodological quality of included studies - part two
Author, yr Reliability Measureme
Functional capacity
Brunelli 2012 [43] x x
England 2012 [44] x x
Jones 2012 [40] x x
Brunelli 2010 [31] x x
Pancieri 2010 [22] x x
Kasymjanova 2009 [25] x x
Brunelli 2008a [34] x x
Brunelli 2008b [33] x x
Koegelenberg 2008 [29] x x
Nikolic 2008 [36] x x
Brunelli 2007 [20] x x
Mao 2007 [26] x x
Saad 2007 [24] x x
Toker 2007 [37] x x
Win 2006 [30] x x
Brunelli 2005 [42] x x
Brunelli 2004 [35] x x
Win 2004 [64] x x
Brunelli 2003 [21] x x
Parsons 2003 [39] x x
Brunelli 2002 [32] x x
Pate 1996 [38] x x
Pierce 1994 [23] x x
Holden 1992 [41] x x
Physical activity
Maddocks 2012 [47] x x
Novoa 2011 [51] x x
Grutsch 2011a, 2011b; Du-Quiton 2010 [48-50] x x
Maddocks 2010 [46] x x
Muscle strength
Trutschnigg 2008 [28] Poor (intra-r) x
Brown 2005 [53] x x
Knols 2002 [52] Fair (inter-r) Fair
Abbreviations: inter-r, inter-rater reliability; intra-r, intra-rater reliability; yr, year publi
x = not assessed.(6MWT) and incremental-shuttle walk test (ISWT)
performed the best out of the 13 tests reviewed, primarily
due to lack of studies investigating measurement properties
of the other 10 tests (Table 1).
Functional capacity The 6MWT, twelve-minute walk-
ing test (12MWT), ISWT, endurance-shuttle walking
test (ESWT) and stair-climbing test are field tests
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http://www.biomedcentral.com/1471-2407/13/135inter or intra-rater reliability, measurement error or re-
sponsiveness of these tests in participants with NSCLC.
The criterion-concurrent validity of the ISWT and stair-
climbing test against the gold standard cardio-pulmonary
exercise test (CPET) was reported by three studies
(Table 4) [29-31]. The ISWT was validated against CPET
(VO2peak) with strong correlation (r=0.67) [30]. The stair-
climbing test (ascent speed) was validated against CPET
(maximum oxygen consumption VO2max) with strong
correlation (r2=0.77) [29].
The criterion-predictive validity of the 6MWT, ISWT
and stair-climbing test were reported and these instru-
ments were shown to predict post-operative outcomes
(studies n=12) [20-24,32-38], post-operative length of
hospital stay (n=1) [39] and survival (n=8) (Table 4)
[23,25,30,33,40-43]: Pre-operative stair-climbing test was
a predictor for post-operative complications when using
variables: test duration [36], oxygen saturation [34,36,37]
or altitude [32-35,38]. Pre-operative 6MWT was a pre-
dictor for post-operative respiratory failure (p<0.05) [23].
Pre-operative stair-climbing test was a predictor for
post-operative length of stay (r=0.34) [39] and hospital
cost (coefficient=2160.2) [33]; and 6MWT was a predictor
for post-operative health related quality of life (HRQoL)
physical domains (GEE=0.001) [24]. The 6MWT was
shown in two papers to predict survival in advanced
NSCLC (hazard ratios=0.44 [25] and 0.48 [40]). With
every 50 m improvement in 6MWT, survival improved by
13% [40] and patients walking ≥ 400 m pre-chemotherapy
had greater survival time [25]. In the post-operative
population survival was predicted by pre-operative
ISWT (area under the ROC curve=0.7) [30]; stair-climbing
test (steps climbed) (p<0.05) [41]; stair-climbing test
(altitude) (coefficient=0.91 [33]; hazard ratio=0.5 [43]) and
inability to perform stair-climbing test (odds ratio=0.2) [42].
A pre-operative stair-climbing test result of >44steps pre-
dicted post-operative survival at 30 days (positive predictive
value=91%, negative predictive value=80%) [41].
Three studies reported on the construct validity of
the 6MWT and ISWT: The 6MWT was validated against
respiratory function tests (forced expired volume in one-
second) with strong correlation (r=0.53) [26]. The ISWT
was validated with moderate correlation against inspira-
tory muscle strength (r=0.42) [44] and isokinetic muscle
dynamometry (r=0.39) (Table 4) [44].
Physical activity No studies validated accelerometers or
pedometers against the gold standard measure of physical
activity (direct calorimetry) [45] or investigated reliability,
measurement error or responsiveness. Four studies investi-
gated construct validity (Table 4): The ActivPAL™ acceler-
ometer (step count) was validated against ActivPAL™
(estimated energy expenditure) with strong correlation
(r=−0.91) [46] and Eastern Cooperative Oncology Group(ECOG) Performance-Scale (p<0.05) [47]. The Actigraph
(accelerations/minute) was validated with medium correl-
ation against the Hospital Anxiety and Depression Scale
(depression) (r=−0.41) [48], the Ferrans and Power Quality
of Life Index Cancer-Version III (HRQoL) (r=0.38-0.57)
[49], the European Organisation for Research and
Treatment of Cancer quality of life questionnaire (loss of
appetite) (r=−0.41) [49]; and with strong correlation against
the Pittsburgh Sleep Quality Index (sleep medication use)
(r=−0.58) [50]. The OMROM Walking Style ProW ped-
ometer (distance walked) was validated against CPET
(VO2max) with moderate correlation (r=0.4) [51].
Muscle strength Only two studies investigated muscle
strength test reliability (Table 1; Additional file 3): The
inter-rater reliability of the MFB50K pulley-gauge
hand-held dynamometer (HHD) (elbow/knee extension)
was very good (ICC=0.90, 0.96 respectively), however meas-
urement error between examiners was large (SEM=10.6,
19.8 respectively), as was the smallest detectable differ-
ence (SDD=29.4, 54.8 respectively) (Additional file 4)
[52]. The Jamar hand-grip dynamometer (HGD) (grip-
strength) intra-rater reliability percent coefficient of
variation was 6.3, which was better than that demon-
strated for HGD with Biodex attachment (%CV16.7)
(Table 1; Additional file 3) [28].
No tests measuring muscle strength were validated against
the gold standard measure (isokinetic dynamometry).
Construct validity was reported for the chair-stand test with
a moderate correlation against Karnofsky Performance
Status (r2=0.56) (Table 4) [53].
Discussion
This review focused on three commonly assessed outcomes
(functional capacity, physical activity and muscle strength)
used in the NSCLC literature [3]. Tests used to evaluate the
effectiveness of exercise in patients with NSCLC must be
reliable and responsive to change in the outcome of
interest, regardless of the cancer stage of participants
and therefore understanding how different NSCLC stages
respond to the outcome measures is vital. Standardised
measures allow generalizability of study results across trials,
which is important in NSCLC, given the poor participant
consent/retention rate [54] and mortality rate. The gold
standard measurement of functional capacity, physical
activity and muscle strength require laboratory tests
which have significant limitations for use in exercise-based
NSCLC research trials. CPET (functional capacity) [7],
direct calorimetry (physical activity) and isokinetic dyna-
mometry (muscle strength) require expensive equipment,
advanced monitoring and experienced technicians. Whilst
limited studies have reported CPET to be safe and feasible
in NSCLC [55], field tests which be performed reliably in
clinical settings may reduce research costs, participant
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use of 13 different field tests and, although a number of
studies investigated the validity of outcome measures in
NSCLC, only two studies investigated reliability, with no
study investigating test responsiveness. Further studies are
needed to establish measurement properties of standardised
field tests for individuals with NSCLC to allow the most
appropriate choice of test when designing research trials.
Functional capacity was the most common outcome of
interest in this review, with the 6MWT most commonly
used. Search 1 retrieved 38 studies utilising the 6MWT in
NSCLC and Search 2 retrieved seven studies investigating
6MWT measurement properties. Only 51% (n=17/33) of
studies published after 2002, using the 6MWT in Search
1, referenced the American Thoracic Society guidelines in
their methodology [56]. Three studies referenced the
guidelines but stated they performed only one 6MWT
during a testing session. Two tests have been shown to
enhance reliability in other populations, with reports
demonstrating the second 6MWT increases by 9-15 m
[56,57]. The encouragement used in the 6MWT in part
one studies was variable. No studies identified in part two
of this review analysed the reliability of the 6MWT. Simi-
larly, in Search 1, 14 studies used the 6MWT to evaluate
the benefit of exercise intervention over time, however no
studies in Search 2 investigated the responsiveness of the
6MWT in any stage of NSCLC. In comparison, there has
been a substantial amount of work regarding the criterion-
predictive validity of the 6MWT in patients with NSCLC.
Results demonstrated the 6MWT was predictive for
post-operative complications, HRQoL and survival.
The 6MWT has not been validated against CPET in
NSCLC, however it has been validated against CPET in
populations with cardiorespiratory disease with moderate
correlations (r=0.51–0.93) [58-61]. Given the frequent use
of the 6MWT, establishing reliability, measurement error,
minimal clinically important difference, responsiveness
and validating the 6MWTagainst CPET in NSCLC should
be a priority.
In Search 1 the ISWT was used in six studies involving
participants with NSCLC and twice this was to evaluate
the benefit of exercise [62,63]. Only fifty percent of the
studies described how the participant was monitored
during the test [30,44,64], however all studies referenced
their procedure, most (n=5/6, 83%) referencing the
original protocol when the test was created [65]. The
ISWT was only performed once during the testing
session across all studies excluding one. Given no studies
in Search 2 investigated the reliability of this test, similar
to the case with the 6MWT, further research needs to
investigate the best method for completing it in NSCLC
to determine if a familiarisation effect is present.
The 12MWTand the ESWT have been infrequently used
in studies of NSCLC and neither test was investigatedregarding its measurement properties in NSCLC. Currently
the alternative 6MWT and ISWT appear to be better
choices of tests until further research is completed.
Search 1 identified 21 studies utilising the stair-climbing
test in NSCLC, all in pre-lung resection candidates. No
studies have used the stair-climbing test to evaluate exer-
cise intervention. Currently there is no gold standard
method to perform the stair-climbing test. Published stud-
ies used variable instructions, encouragement, monitoring
and experience of assessors. Some authors reported the
number of steps/altitude whilst others reported test
duration. Results of Search 2 consistently demonstrated
the stair-climbing test to be valuable in the pre-operative
evaluation of lung resection candidates, with the stair-
climbing test providing prediction validity with regard to
post-operative complications, length of stay, mortality and
hospital cost. The stair-climbing test has also been
validated against the gold standard (CPET). No studies
evaluated reliability; measurement error or responsiveness
in NSCLC and therefore it is currently not known if this is
a suitable test to evaluate exercise interventions, especially
in post-operative and chemo-radiation cohorts.
Search 1 demonstrated that physical activity has been
measured in participants with NSCLC using accelerometers
and pedometers. Search 2 showed that accelerometers and
pedometers have not been validated against the gold stand-
ard measure (direct calorimetry) in NSCLC. Direct calorim-
etry has limitations and accelerometers are commonly the
preferred method to measure physical activity [66,67].
However, accelerometers and pedometers are limited in
that they rely on participant compliance. In the NSCLC
literature, few studies are conducted measuring physical
activity levels and even fewer studies have investigated the
measurement properties associated with tests.
Muscle strength was measured using five different
tests by 17 studies in sSarch 1. Search 2 retrieved three
studies evaluating measurement properties of only three
of the five instruments. All three studies were conducted
with mixed cancer cohorts and the methodological quality
of each study was ‘poor’ or ‘fair’: therefore results need to
be interpreted with caution. Hand dynamometry was the
most commonly used instrument to assess muscle
strength in part one studies. Two hand-dynamometry
devices were tested for reliability however results were not
strong enough to recommend use of a particular device.
Whilst both HHD and HGD have been shown to be
reliable and valid in many patient populations, further
research needs to be performed in NSCLC [68-70]. Man-
ual muscle testing is often considered to be qualitative
and frequently performed in profoundly weak populations
such as those with critical illness [71,72]. Four studies in
Search 1 used MMT to measure upper-body strength on
repeated occasions however the measurement properties
have not been established. This review demonstrated that
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chair-stand test have been used in NSCLC, however there
is currently insufficient research to support the use of one
measure over another.
Limitations
To minimise risk of selection bias two independent re-
viewers were utilised. In Search 2 articles were excluded if
cancer type was unconfirmed. There is a risk of publication
bias, where studies which have found poor measurement
properties have not been published. Given that registration
of studies evaluating measurement properties is not
standard practice, the extent of this is unknown [8].
The COSMIN checklist was not completed in its entirety
and may have also under-estimated methodological quality
because the rating of each item was determined using the
lowest score rather than the average or highest score.
Due to the small number of studies evaluating meas-
urement properties of the included outcome measures
in cohorts with only NSCLC participants, this review
included studies with mixed cancer types (providing at
least five participants had NSCLC). Different cancer
types are associated with heterogeneous symptom profiles
(for example dyspnoea and pain), gas exchange and exercise
capacity. Therefore findings from the studies with mixed
cancer types must be interpreted with caution when
extrapolated for use in NSCLC. Additionally there was
heterogeneity with regards to the participants in the
included studies (particularly age and treatment exposure)
(Table 2). This may explain, in part, the variance in
data obtained and large standard deviations reported
by individuals studies (Additional file 4) because age,
comorbidities (such as COPD) and treatment (such as
chemotherapy) directly impact exercise capacity and
performance as well as the disease of NSCLC.
Conclusion
Measurements of functional capacity, physical activity
and muscle strength are commonly used as outcomes
for individuals with NSCLC participating in exercise
trials. The 6MWT, 12MWT, ISWT, ESWT and stair-
climbing test have been used to assess functional capacity
in NSCLC. Only two tests (ISWT and stair-climb test)
were validated against CPET, the gold standard measure
of functional capacity. Physical activity has been measured
using accelerometers and pedometers: there was some evi-
dence for construct validity but neither had been validated
against the gold standard or tested for reliability. Muscle
strength has been measured using HHD, HGD, manual
muscle test, 1RM and the chair-stand test. Only two
strength measures were tested for their reliability in
NSCLC, and there was insufficient evidence to support
the use of one strength measure over another. Responsive-
ness and minimal important clinical difference was notestablished for any of the 13 tests. Currently there is an
important gap in the literature regarding the measurement
properties of commonly used tests in NSCLC and further
research needs to be conducted in this area to improve
the clinical use and applicability of these tests in patients
with NSCLC.
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Additional file 1: Flow diagram of outcome measures selection
process – Search 1 [11]. Abbreviations: Ax, assessment; CINAHL,
Cumulative Index to Nursing and Allied Health Literature; DARE, Database of
Abstracts and Reviews of Effects; EMBASE, the Excerpta Medica Database; FT,
full text; n, number; NSCLC, non-small cell lung cancer; OM, outcome
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outcome measure.
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E1, examiner one; E2, examiner two; Elb, elbow; E, extension; ECOG,
Eastern Cooperative Oncology Group; ft, feet; gp, group; HGS, hand grip
strength; hrs, hours; inpt, inpatients; IQR, inter-quartile range; ISWT,
incremental-shuttle walk test; kg, kilogram; lbs, pounds; m, meters; MIC,
minimal important change; min, minutes; ml, millilitres; N, newtons;
outpt, outpatient; O2desat, oxygen desaturation; POC, post-operative
complication; post-op, post-operative; pre-op, pre-operative; PS,
performance status; RT, radiotherapy; s, seconds; SCT, stair-climb test; SD,
standard deviation; SDD, smallest detectable difference; VO2peak, peak
oxygen consumption; yr, year published.* results presented from most
recent publication.
Additional file 4: Inter-rater reliability, intra-rater reliability and
measurement error associated with outcome measures.
Abbreviations: 95% CI, 95% confidence intervals;%CV, percent coefficient
of variation; b/t, between; E, extension; Elb, elbow; HGD, hand-grip
dynamometry; HHD, hand-held dynamometry; ICC, intraclass correlation
coefficient; mean diff, mean difference for repeated measures; min,
minutes, OM, outcome measure; NR, not reported; SEM, standard error of
measurement.
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